Results 261 to 270 of about 2,984,719 (362)

Editorial: Predictive and prognostic value of liquid biopsy biomarkers in metastatic cancers: from basic science, across high throughput profiling up to clinical practice

Frontiers in Oncology
Dorota Kwapisz, Patrycja Pawlikowska, Areti Strati   +2 more
doaj   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts

Signal Transduction and Targeted Therapy
Marina Kolesnichenko, Claus Scheidereit
doaj   +1 more source

Tumor cells escape immunosurveillance by hampering LFA-1. [PDF]

Front Immunol
Upadhyay S, Murugu L, Svensson L.
europepmc   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

RNAi Screening in Tumor Cells Identifies Artificial microRNAs That Improve Oncolytic Virus Replication. [PDF]

Pharmaceuticals (Basel)
Klemets H, Bardoul A, Pelin A, Singaravelu R, Boileau M, Falls T, Petryk J, Bourgeois-Daigneault MC, Bell JC, Roy DG.   +9 more
europepmc   +1 more source

RETRACTION: lncRNA‐PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway

Molecular Oncology, EarlyView.
RETRACTION: W. Pan, W. Li, J. Zhao, Z. Huang, J. Zhao, S. Chen, C. Wang, Y. Xue, F. Huang, Q. Fang, J. Wang, D. Brand, and S. G. Zheng, “lncRNA‐PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway,” Molecular Oncology 13, no. 10 (2019): 2246–2258, https://doi.org/10.1002/1878-0261.12553.
wiley   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Precise photopharmacological eradication of metastatic tumor cells.

Dis Model Mech
Varady A, Grissenberger S, Wenninger-Weinzierl A, Poplimont H, Sturtzel C, Schmitner N, Gao L, Kimmel RA, Distel M.   +8 more
europepmc   +1 more source

SDC4 identified as an oncogenic target gene of NF-κB in TNFα-Induced tumor cells. [PDF]

Sci Rep
Zhou F, Li Y, Tang Z, Chen C, Xie X, Li Y, Chen Z, Zou X, Zhu H.   +8 more
europepmc   +1 more source